Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intensity Therapeutics Inc (INTS)

Intensity Therapeutics Inc (INTS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,028
  • Shares Outstanding, K 60,065
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,270 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 3.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.83
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.63
  • Most Recent Earnings $-0.06 on 11/06/25
  • Next Earnings Date 03/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.06
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +77.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2450 +2.12%
on 02/13/26
0.4429 -43.51%
on 01/20/26
-0.1677 (-40.13%)
since 01/13/26
3-Month
0.2450 +2.12%
on 02/13/26
0.6000 -58.30%
on 12/12/25
-0.2279 (-47.67%)
since 11/13/25
52-Week
0.1853 +35.02%
on 08/01/25
2.4996 -89.99%
on 03/19/25
-1.9198 (-88.47%)
since 02/13/25

Most Recent Stories

More News
Intensity Therapeutics Announces Reverse Stock Split

Intensity's common stock is expected to begin trading on a post-split adjusted basis on February 19, 2026

INTS : 0.2502 (-32.58%)
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026

INTS : 0.2502 (-32.58%)
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

SHELTON, Conn. , Dec. 11, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.2502 (-32.58%)
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

SHELTON, Conn. , Dec. 5, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.2502 (-32.58%)
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

SHELTON, Conn. , Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.2502 (-32.58%)
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

SHELTON, Conn. , Nov. 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.2502 (-32.58%)
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

SHELTON, Conn. , Oct. 31, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and...

INTS : 0.2502 (-32.58%)
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

The paper features a comprehensive evaluation of data, including disease control rate, overall survival, immune activation, abscopal effects, tumor necrosis, dose ranging, and safety

INTS : 0.2502 (-32.58%)
Precision Oncology Pipeline Advances from Detection Through Targeted Destruction

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Major biotechnology companies are presenting multi-cancer detection data and breakthrough clinical results...

INTS : 0.2502 (-32.58%)
GRAL : 97.50 (+1.68%)
GTBP : 0.4636 (-1.49%)
PFE : 27.58 (+0.40%)
CCCC : 1.8900 (+3.28%)
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

SHELTON, Conn. , Sept. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery...

INTS : 0.2502 (-32.58%)

Business Summary

Intensity Therapeutics Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx(SM) technology platform to create new, proprietary drug formulations, following direct injection, rapidly disperse throughout a tumor...

See More

Key Turning Points

3rd Resistance Point 0.3233
2nd Resistance Point 0.3066
1st Resistance Point 0.2784
Last Price 0.2502
1st Support Level 0.2335
2nd Support Level 0.2168
3rd Support Level 0.1886

See More

52-Week High 2.4996
Fibonacci 61.8% 1.6155
Fibonacci 50% 1.3424
Fibonacci 38.2% 1.0694
Last Price 0.2502
52-Week Low 0.1853

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar